Motor and Nonmotor Features of p.A53T Alpha-Synuclein PD vs idiopathic PD: Longitudinal Data from the PPMI Study.
Athina Maria Simitsi,Evangelos Sfikas,Christos Koros,Nikolaos Papagiannakis,Ion Beratis,Dimitra Papadimitriou,Roubina Antonelou,Styliani Fragkiadaki,Dionysia Kontaxopoulou,Marina Picillo,Ioanna Pachi,Ioanna Alefanti,Maria Stamelou,Paolo Barone,Leonidas Stefanis
DOI: https://doi.org/10.1101/2024.08.23.24312442
2024-08-23
Abstract:Background and Objectives:
The phenotype of p.A53T-SNCA Parkinson's Disease (PD) mutation carriers appears more severe than that of iPD patients, however comprehensive comparative prospective studies are lacking. Here we conducted a longitudinal study to investigate, using multiple parameters, the progression of motor and nonmotor features of p.A53T-PD compared to iPD.
Methods:
Longitudinal 3-year data, concerning both motor and non-motor features, of 16 p.A53T-PD and 48 iPD, matched for age and disease duration at baseline, were downloaded from the Parkinson's Progression Markers Initiative (PPMI) database and compared between the two groups. Additionally, a cognitive composite score was generated by 5 cognitive tests, focused on executive/visuospatial function to better study cognitive change.
Results:
Neuropsychological assessments of global cognitive (MOCA), and especially executive/visuospatial function, reflected in the composite score, revealed significant cognitive decline in A53T-PD compared to iPD, but also across time for the group of A53T-PD. Autonomic dysfunction and items of MDS-UPDRS I, reflecting global cognitive function and psychotic features, were more prominent in A53T-PD. Motor assessments showed worse performance in A53T-PD, even though LEDD was significantly higher in A53T-PD.
Discussion:
The current longitudinal study indicates that A53T-PD represents a rapidly progressing subtype of PD, with accelerated decline in both motor and non-motor parameters, especially in cognitive function. Such data may set the stage for the application of targeted disease-modifying therapies in this particular subtype, in which the etiological link to alpha-synuclein is established, while generated data may be relevant to iPD, which is largely a sporadic synucleinopathy.
Neurology
What problem does this paper attempt to address?